UCB (UCB) Aktievy
UCB SA är ett biofarmaceutiskt företag som utvecklar produkter och lösningar för människor med neurologiska och immunologiska sjukdomar över hela världen. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 5/6 |
| Framtida tillväxt | 3/6 |
| Tidigare resultat | 5/6 |
| Finansiell hälsa | 6/6 |
| Utdelningar | 0/6 |
Belöningar
Riskanalys
Inga risker upptäckta för UCB från våra riskkontroller.
UCB Community Fair Values
Create NarrativeSee what 37 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
UCB SA Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | €237.10 |
| 52 veckors högsta | €289.50 |
| 52 veckors lägsta | €168.45 |
| Beta | 0.20 |
| 1 månads förändring | -10.33% |
| 3 månaders förändring | -13.78% |
| 1 års förändring | 38.70% |
| 3 års förändring | 198.92% |
| 5 års förändring | 166.28% |
| Förändring sedan börsintroduktionen | 77,603.06% |
Senaste nyheter och uppdateringar
Uppdatering av berättelse • Jun 24
UCB: Pipeline And Execution Risks Will Eventually Challenge Rich Earnings Expectations
Analysts have trimmed their price target for UCB slightly to about €219 from roughly €222, citing modest adjustments to revenue growth expectations, partly offset by slightly stronger projected profit margins and a marginally lower future P/E assumption. Analyst Commentary Recent research on UCB points to a more cautious tone around the stock, with the trimmed price target to about €219 reinforcing the idea that analysts see less room for upside than before.Uppdatering av berättelse • Jun 05
UCB: Epilepsy Reliance Will Eventually Clash With Lupus And Pipeline Uncertainty
UCB's analyst price target has been raised from €209.22 to €221.55, with analysts pointing to updated assumptions around slightly higher projected revenue growth, a modestly higher discount rate, broadly steady profit margins, and a small adjustment to future P/E expectations. Analyst Commentary Recent Street research on UCB highlights that not all analysts are leaning in the same direction, even with a higher price target.Recent updates
Uppdatering av berättelse • Jun 24
UCB: Pipeline And Execution Risks Will Eventually Challenge Rich Earnings Expectations
Analysts have trimmed their price target for UCB slightly to about €219 from roughly €222, citing modest adjustments to revenue growth expectations, partly offset by slightly stronger projected profit margins and a marginally lower future P/E assumption. Analyst Commentary Recent research on UCB points to a more cautious tone around the stock, with the trimmed price target to about €219 reinforcing the idea that analysts see less room for upside than before.Uppdatering av berättelse • Jun 05
UCB: Epilepsy Reliance Will Eventually Clash With Lupus And Pipeline Uncertainty
UCB's analyst price target has been raised from €209.22 to €221.55, with analysts pointing to updated assumptions around slightly higher projected revenue growth, a modestly higher discount rate, broadly steady profit margins, and a small adjustment to future P/E expectations. Analyst Commentary Recent Street research on UCB highlights that not all analysts are leaning in the same direction, even with a higher price target.
Uppdatering av berättelse • May 15
UCB: Epilepsy Blockbusters And Neuroscience Pipeline Will Drive Future Upside Potential
Analysts have nudged their average price target for UCB higher, with fair value moving from €284.65 to about €288.21 as they factor in updated assumptions on discount rate, revenue growth, profit margins, and future P/E, supported by recent target hikes and fresh Outperform ratings on the stock. Analyst Commentary Recent research points to a split but constructive view on UCB, with several firms adjusting ratings and targets as they reassess the stock's risk and reward profile.
Uppdatering av berättelse • Apr 30
UCB: Epilepsy Portfolio Execution To Drive Future Earnings Power Upside
The analyst fair value estimate for UCB has shifted from €310 to €340, reflecting updated assumptions on revenue growth, higher projected profit margins, a slightly adjusted discount rate, a revised future P/E, and recent Street research in which analysts highlight UCB's epilepsy portfolio and reset price targets in the €300 to €340 range. Analyst Commentary Recent Street research on UCB has been mixed, with some caution on near-term risk and reward but also clear pockets of optimism tied to its neuroscience and epilepsy franchises.Uppdatering av berättelse • Apr 16
UCB: Epilepsy And Neuroscience Execution Will Shape Balanced Risk Reward Profile
Analysts have adjusted the UCB price target toward €285, reflecting a blend of more cautious views that see risk and reward as balanced around €260 and more optimistic calls pointing toward €304 to €340, supported by expectations for its epilepsy portfolio and broader neuroscience exposure. Analyst Commentary Bullish Takeaways Bullish analysts see upside toward €304 to €340, suggesting that current pricing does not fully reflect expectations around the epilepsy portfolio and broader neuroscience pipeline.Uppdatering av berättelse • Apr 01
UCB: Epilepsy Franchise And Dermatology Data Will Shape Future Risk Reward Balance
Narrative Update on UCB The analyst price target for UCB has been adjusted slightly lower to about €285. This reflects a blend of more cautious views that see a balanced risk and reward at current levels, and more optimistic targets that highlight UCB's epilepsy portfolio and recent upward revisions from several banks.Uppdatering av berättelse • Mar 18
UCB: Epilepsy And Psoriatic Arthritis Execution Will Shape Future Risk Reward Balance
The updated analyst price target for UCB moves to €284.85 from €275.74. This reflects a mix of more conservative revenue growth assumptions, higher expected profit margins, and a lower future P/E multiple, in line with recent research that balances enthusiasm around epilepsy assets with a more measured view on risk and reward.Uppdatering av berättelse • Mar 04
UCB: Epilepsy Franchise Expectations Will Eventually Strain Current Share Price
We are lifting our fair value estimate for UCB from €173.07 to €209.22, reflecting higher assumed revenue growth and profit margins as analysts highlight a stronger outlook for the epilepsy franchise and raise price targets into the €300+ range. Analyst Commentary Recent Street research on UCB has centered on the epilepsy franchise and the broader neuroscience portfolio, with several firms updating their views and price targets.Uppdatering av berättelse • Feb 18
UCB: Epilepsy Pipeline Progress And Execution Will Shape Future Upside Balance
Our Analyst Price Target for UCB has moved higher from €261.42 to €275.74, reflecting analysts' updated assumptions on revenue growth, profitability and P/E in light of recent Street target lifts to around €304 to €310. Analyst Commentary Recent Street research on UCB has centered on higher price targets, with bullish analysts adjusting their views to reflect updated assumptions on revenue, profitability and P/E.Uppdatering av berättelse • Feb 04
UCB: Future Earnings Power To Reflect Rare Disease And Epilepsy Execution
Analysts have raised their price target on UCB to €310 from €270, citing updated assumptions for revenue growth, profit margins and a slightly lower future P/E multiple as the main drivers of the change. Analyst Commentary Recent commentary from bullish analysts has centered on higher valuation support for UCB, with the new €310 price target used as a reference point for what they see as stronger execution and earnings potential than previously modeled.Uppdatering av berättelse • Jan 21
UCB: Late-Stage Pipeline And Margin Execution Will Shape Balanced Upside Potential
Analysts raised their price target on UCB to €310 from €270, citing updated expectations for slightly stronger revenue growth, improved profit margins, and a modestly lower future P/E multiple. Analyst Commentary Bullish Takeaways Bullish analysts point to the higher €310 target as a sign that they see current valuation as not fully reflecting updated revenue and margin expectations.Uppdatering av berättelse • Jan 07
UCB: Raising Future Fair Value On Strengthening Rare Disease And Epilepsy Franchise
Analysts have raised their fair value estimate for UCB from €255 to €310, citing recent price target increases from the Street and updated assumptions on revenue growth, profit margins and future P/E levels. Analyst Commentary Bullish analysts have recently adjusted their views on UCB, with fresh price targets that now cluster around €290 to €310.Uppdatering av berättelse • Dec 18
UCB: Expanding Late-Stage Pipeline And New Launches Will Drive Future Upside
UCB's analyst price target has been raised from EUR 258.33 to EUR 264.67 as analysts factor in slightly stronger revenue growth expectations, despite a modestly lower projected profit margin and only a small uptick in future valuation multiples. Analyst Commentary Recent price target increases signal that bullish analysts see a more attractive risk reward profile for UCB, driven by improving growth visibility and confidence in execution.Uppdatering av berättelse • Dec 04
UCB: Pipeline Execution And New Launches Will Support Balanced Future Upside Potential
UCB's fair value estimate has been nudged higher to approximately EUR 258 from EUR 257, reflecting analysts' upward revisions to price targets, with recent moves to EUR 240, EUR 285 and EUR 290. These changes highlight confidence in the company's earnings trajectory despite slightly softer margin and growth assumptions.Uppdatering av berättelse • Nov 20
UCB: Recent Pipeline Advances And Margin Strength Will Drive Share Price Higher
Analysts have slightly raised their fair value estimate for UCB to €256.67. They cite recent upward revisions to price targets, supported by continued expectations for stable profit margins and healthy revenue growth.Analysartikel • Nov 11
UCB (EBR:UCB) Could Easily Take On More Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Uppdatering av berättelse • Nov 06
UCB: Strong Profit Margins And Momentum Will Drive Shares Higher
UCB's fair value estimate has increased by approximately EUR 4.50, as analysts highlight robust performance and upward revisions to price targets. This follows renewed confidence in the company’s profit margin outlook.Uppdatering av berättelse • Oct 22
Analysts Raise UCB Price Targets Amid Positive Sector Outlook and Improved Growth Forecasts
UCB's analyst price target has been raised from €240.28 to €251.11, as analysts cite upward revisions to revenue growth forecasts along with an improved sector outlook. Analyst Commentary Recent analyst actions reflect a strongly positive sentiment toward UCB's outlook, as multiple firms have revised their price targets upward and maintained favorable ratings.Analysartikel • Oct 14
Market Participants Recognise UCB SA's (EBR:UCB) Earnings Pushing Shares 25% Higher
UCB SA ( EBR:UCB ) shares have continued their recent momentum with a 25% gain in the last month alone. Looking back a...Uppdatering av berättelse • Oct 08
Aging Populations And Emerging Markets Will Unlock Opportunity
UCB's analyst price target has been increased from €229.06 to €240.28. This change reflects improved revenue growth expectations and profit margins highlighted by recent analyst updates.Uppdatering av berättelse • Sep 24
Aging Populations And Emerging Markets Will Unlock Opportunity
The slight increase in UCB’s consensus price target to €229.06 reflects improved revenue growth forecasts, while profit margin expectations remain stable. What's in the News Three-year data from BE HEARD trials show sustained efficacy and quality of life improvements with BIMZELX® in moderate-to-severe hidradenitis suppurativa, with better outcomes linked to earlier treatment.Uppdatering av berättelse • Aug 27
Aging Populations And Emerging Markets Will Unlock Opportunity
Analysts have raised their price target for UCB to €223.17, citing robust fundamentals, resilient earnings growth, and improved confidence in management despite recent share price weakness. Analyst Commentary Recent share price pullback seen as disconnected from underlying business strength.Analysartikel • Jul 17
UCB SA (EBR:UCB) Not Lagging Market On Growth Or Pricing
When close to half the companies in Belgium have price-to-earnings ratios (or "P/E's") below 14x, you may consider UCB...
Ny berättelse • Mar 02
BIMZELX's Successful Launch Will Expand Future Market Opportunities In Dermatology And Rheumatology
UCB's new product launches and high R&D success rate are driving anticipated revenue and margin growth across global markets.Aktieägarnas avkastning
| UCB | BE Pharmaceuticals | BE Marknad | |
|---|---|---|---|
| 7D | -8.6% | -3.5% | -2.4% |
| 1Y | 38.7% | 13.1% | 23.0% |
Avkastning vs industri: UCB översteg Belgian Pharmaceuticals branschen som gav 13.1 % under det senaste året.
Avkastning vs Marknaden: UCB översteg Belgian marknaden som gav 23 % under det senaste året.
Prisvolatilitet
| UCB volatility | |
|---|---|
| UCB Average Weekly Movement | 4.3% |
| Pharmaceuticals Industry Average Movement | 5.3% |
| Market Average Movement | 3.8% |
| 10% most volatile stocks in BE Market | 7.0% |
| 10% least volatile stocks in BE Market | 2.3% |
Stabil aktiekurs: UCB har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för Belgian.
Volatilitet över tid: UCB s veckovolatilitet ( 4% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 1925 | 9,765 | Jean-Christophe Tellier | www.ucb.com |
UCB SA är ett biofarmaceutiskt företag som utvecklar produkter och lösningar för människor med neurologiska och immunologiska sjukdomar över hela världen. Företagets huvudprodukter omfattar Cimzia för inflammatoriska TNF-medierade sjukdomar, liksom ankyloserande spondylit (AS), axial spondylartrit, Crohns sjukdom, icke-radiografisk axial spondylartrit, plackpsoriasis, psoriasisartrit och reumatoid artrit; Vimpat, Keppra och Briviact för epilepsi; och Neupro för Parkinsons sjukdom och restless legs syndrom. Företaget tillhandahåller också Nayzilam, en räddningsbehandling i form av nässpray för epileptiska anfall, samt Zyrtec och Xyzal mot allergier.
UCB SA Sammanfattning av grunderna
| UCB grundläggande statistik | |
|---|---|
| Börsvärde | €47.59b |
| Vinst(TTM) | €1.56b |
| Intäkter(TTM) | €7.74b |
29.0x
P/E-förhållande5.8x
P/S-förhållandeÄr UCB övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| UCB resultaträkning (TTM) | |
|---|---|
| Intäkter | €7.74b |
| Kostnad för intäkter | €1.99b |
| Bruttovinst | €5.75b |
| Övriga kostnader | €4.19b |
| Intäkter | €1.56b |
Senast redovisade vinst
Dec 31, 2025
Nästa vinstdatum
Jul 30, 2026
| Vinst per aktie (EPS) | 8.18 |
| Bruttomarginal | 74.29% |
| Nettovinstmarginal | 20.13% |
| Skuld/egenkapitalförhållande | 19.0% |
Hur har UCB utvecklats på lång sikt?
Se historisk utveckling och jämförelseUtdelningar
0.6%
Aktuell utdelningsavkastning18%
UtbetalningskvotFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/07/10 17:53 |
| Aktiekurs vid dagens slut | 2026/07/10 00:00 |
| Intäkter | 2025/12/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa denna rapport finns på vår Github-sida; vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
UCB SA bevakas av 37 analytiker. 16 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Charles Pitman | Barclays |
| Brian Bourdot | Barclays |
| Kerry Holford | Berenberg |